Actuate Therapeutics (NASDAQ:ACTU) Coverage Initiated at HC Wainwright

HC Wainwright began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research report issued on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 168.10% from the stock’s current price.

Actuate Therapeutics Trading Up 0.8 %

Shares of Actuate Therapeutics stock opened at $7.46 on Monday. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.73. The business’s fifty day moving average price is $8.15 and its 200 day moving average price is $8.07.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACTU. BIOS Capital Management LP acquired a new position in Actuate Therapeutics in the fourth quarter valued at $78,753,000. Voss Capital LP acquired a new position in shares of Actuate Therapeutics during the fourth quarter worth about $440,000. Northwestern University acquired a new position in shares of Actuate Therapeutics during the third quarter worth about $207,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Actuate Therapeutics during the fourth quarter worth about $130,000. Finally, Sigma Planning Corp acquired a new position in shares of Actuate Therapeutics during the fourth quarter worth about $128,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.